Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25495045 | 0.87 | CYP4F2 (0.32) | CYP19A1CYP4F2CYP4A11 | |
| SCHEMBL24334522 | 0.85 | — | — | |
| SCHEMBL24333904 | 0.83 | — | — | |
| SCHEMBL24334766 | 0.82 | — | — | |
| SCHEMBL21093199 | 0.79 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL22791067 | 0.78 | CYP4F2 (0.32) | CYP4F2CYP4A11 | |
| SCHEMBL22787018 | 0.70 | CYP4F2 (0.30) | CYP4F2CYP4A11 | |
| SCHEMBL26441051 | 0.70 | — | — | |
| SCHEMBL22701246 | 0.69 | — | — | |
| SCHEMBL22787042 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744896-B2 | Compositions, use, and method for CDK2-PROTACs for cancer therapy and hearing loss | CREIGHTON UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220096642-A1 | COMPOSITIONS, USE, AND METHOD FOR CDK2-PROTACS FOR CANCER THERAPY AND HEARING LOSS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096642-A1 | COMPOSITIONS, USE, AND METHOD FOR CDK2-PROTACS FOR CANCER THERAPY AND HEARING LOSS | CDK2, CDK20, CDK2AP2 | CYP19A1 4055/4885CYP4F2 4742/4885CYP4A11 4720/4885 |
| US-11744896-B2 | Compositions, use, and method for CDK2-PROTACs for cancer therapy and hearing loss | CDK2, CDK20, CDK2AP2 | CYP19A1 4055/4885CYP4F2 4742/4885CYP4A11 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.